Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Income: 2009-2025

Historic Net Income for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Net Income rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 112.80%. This contributed to the annual value of $16.9 million for FY2024, which is 119.58% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Net Income is $5.9 million, which was up 276.65% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Net Income peaked at $51.6 million during Q2 2022, and registered a low of -$101.8 million during Q4 2023.
  • Moreover, its 3-year median value for Net Income was $3.8 million (2023), whereas its average is -$5.3 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 453.20% in 2021, then spiked by 359.09% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Net Income (Quarterly) stood at -$20.3 million in 2021, then slumped by 41.75% to -$28.8 million in 2022, then tumbled by 253.66% to -$101.8 million in 2023, then spiked by 99.57% to -$433,000 in 2024, then spiked by 107.84% to $5.9 million in 2025.
  • Its Net Income stands at $5.9 million for Q3 2025, versus $1.6 million for Q2 2025 and $3.7 million for Q1 2025.